Overcoming the blood-brain barrier to potentiate GD2-CAR T therapy using P-selectin-targeted nanomedicine (AACR 2026) - Mar 18, 2026 - Abstract #LB329/10; Pres time: Apr 21, 2026; 02:00 PM - 05:00 PM; Location: Section 52; "To overcome these challenges, we engineered radiation-guided, P-selectin-targeted PLGA-PEG-(SO3)2 nanoparticles (sNPs) encapsulating the multikinase inhibitor zotiraciclib (TG02) and explored a combination therapy using GD2-CAR T cells to further enhance therapeutic efficacy...Overall, this work demonstrates a BBB-penetrant, tumor-selective nanomedicine strategy that enhances the efficacy of GD2-CAR T therapy in pediatric brain tumors. By integrating radiation guidance, targeted drug delivery, and cellular immunotherapy, this platform addresses key barriers in pediatric neuro-oncology and supports further development for DIPG and MB."
CAR T-Cell Therapy • Late-breaking abstract • Brain Cancer • Diffuse Intrinsic Pontine Glioma • Glioma • Medulloblastoma • Oncology • Solid Tumor
|
|
Giuseppe Longobardi1; Adan Miari1; Yulia Liubomirski1; Ester Buderovsky2; Anat Globerson Levin2; Ronit Satchi-Fainaro1
|